On August 04, 2026, Pfizer Inc (NYSE: PFE) reported its second-quarter earnings, surpassing analyst expectations on both earnings per share and revenue. This update comes amid ongoing challenges from legacy products but highlights the company’s continued efforts to explore new growth avenues.
- Pfizer offers a compelling dividend profile with a 6.87% yield, a conservative payout ratio of 56%, and steady dividend growth of 2.4% over the past three years, supported by a GF Value™ verdict that indicates the stock is modestly undervalued.
- The company holds a respectable GF Score™ of 70 out of 100, reflecting balanced financial health, profitability, and valuation metrics.
- Insider activity shows modest selling with no insider purchases in the last three months, while 22 top-tier gurus hold the stock, with 12 adding and 9 trimming positions recently, signaling nuanced institutional confidence.
What's Behind the News?
Pfizer’s second-quarter results demonstrated resilience with a non-GAAP earnings per share of $0.77, beating estimates by $0.09, and revenues of $15.03 billion, exceeding forecasts by $640 million. These figures underscore Pfizer’s ability to deliver solid financial performance despite pressures from its legacy drug portfolio. The company continues to invest in innovation and new growth opportunities, which is critical given the pharmaceutical industry’s competitive and regulatory landscape.
As one of the world’s largest pharmaceutical firms, Pfizer operates primarily in the healthcare sector within the drug manufacturing industry. With a market capitalization of $142.66 billion, Pfizer’s global footprint includes a diverse portfolio of prescription drugs and vaccines, including top sellers like Prevnar 13, Vyndaqel, and Eliquis. International sales account for 40% of total revenue, with emerging markets playing a significant role in growth potential.
Is PFE's Dividend Safe and Attractive?
Pfizer’s dividend profile remains a key attraction for income-focused investors. The current dividend yield stands at an impressive 6.87%, which is notably higher than many peers in the healthcare sector. Coupled with a payout ratio of 56%, the dividend payout is well within a sustainable range, suggesting Pfizer retains enough earnings to support ongoing dividend payments without compromising reinvestment needs. Additionally, the company has maintained a modest dividend growth rate of 2.4% over the past three years, indicating a stable and gradually increasing income stream for shareholders.
Supporting this dividend thesis is Pfizer’s GF Value™ of $25.96 compared to its current share price of $25.03, implying the stock is approximately 3.6% undervalued. This valuation suggests that investors are getting a fair price with a slight margin of safety, reinforcing the attractiveness of Pfizer’s dividend yield. For those interested in the methodology behind GF Value™, which incorporates historical trading multiples, past growth, and future performance estimates, more details can be found here.
What Does PFE's GF Score™ Tell Us?
The GF Score™ is a composite metric designed to evaluate a company’s overall quality by aggregating its financial strength, profitability, growth, valuation, and momentum. Pfizer’s GF Score™ of 70 out of 100 reflects a solid standing, particularly in valuation and profitability, while growth remains a relative weakness.
| Metric | Rating (out of 10) |
|---|---|
| GF Score™ | 70 |
| Financial Strength | 5 |
| Profitability | 7 |
| Growth | 3 |
| Valuation | 9 |
| Momentum | 4 |
Pfizer’s strongest areas are valuation and profitability, scoring 9 and 7 respectively, which aligns with its fair valuation status and solid operating margins (27.24%). However, growth ranks lower at 3, reflecting recent declines in revenue per share and earnings growth over the past few years. Financial strength is moderate at 5, with an Altman Z-Score of 2.04 signaling some financial stress but no immediate bankruptcy risk. Momentum is also subdued at 4, consistent with the stock’s relatively stable price movements. For a deeper dive into Pfizer’s financial metrics, visit the PFE stock page.
What Are Gurus and Insiders Doing with PFE?
Institutional interest in Pfizer remains robust, with 22 premium gurus currently holding the stock. In recent quarters, 12 gurus have increased their positions while 9 have trimmed, indicating a balanced but generally positive sentiment among top investment professionals. This guru activity is a valuable signal unique to GuruFocus, offering insight beyond typical institutional ownership data available on other platforms.
On the insider front, there has been net selling activity over the past three months, with insiders offloading approximately 2,000 shares valued at $51,400, and no insider buying reported. While insider selling can sometimes raise caution, the volume here is modest relative to the company’s size and does not necessarily indicate a negative outlook.
What This Means for Investors
For investors seeking reliable income, Pfizer’s dividend remains both attractive and sustainable, supported by a reasonable payout ratio and consistent dividend growth. The stock’s slight undervaluation per the GF Value™ metric adds an additional layer of appeal, suggesting that investors are not overpaying for this income stream. While growth prospects are muted and financial strength shows some cautionary signals, the broad institutional endorsement from gurus and a solid GF Score™ reinforce Pfizer’s position as a stable dividend stock in the healthcare sector. Investors interested in monitoring Pfizer’s evolving fundamentals and valuation can explore more on the PFE stock page or use the GuruFocus Stock Screener to compare with peers.
Frequently Asked Questions
What is PFE's GF Score™?
PFE’s GF Score™ of 70 out of 100 reflects a balanced assessment of its financial strength, profitability, growth, valuation, and momentum, indicating a generally solid company with some growth challenges.
Is PFE's dividend safe?
Yes, Pfizer’s dividend appears safe with a high yield of 6.87%, a moderate payout ratio of 56%, and steady dividend growth of 2.4% over the past three years, suggesting sustainable income for shareholders.
What is PFE's P/E ratio compared to historical?
Pfizer’s current trailing P/E ratio is 19.11x, which is above its 5-year median P/E of 14.58x, indicating the stock trades at a premium relative to its recent historical valuation.
This stock alert was generated using automated technology and GuruFocus financial data to provide readers with timely and accurate market reporting. This content was reviewed by GuruFocus editorial team prior to publication. Please send any questions or comments about this story to [email protected].
